This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MIS 2 | |
|---|---|
| Name | MIS 2 |
| Specialty | Neonatology; Pediatrics |
MIS 2 MIS 2 is a clinical entity recognized in pediatric and neonatal literature. It presents with a characteristic constellation of systemic, immunologic, and inflammatory findings that distinguish it within a group of postinfectious inflammatory syndromes described in recent decades. Clinicians and researchers from institutions such as World Health Organization, Centers for Disease Control and Prevention, Harvard Medical School, Johns Hopkins University, and Great Ormond Street Hospital have contributed to its evolving nosology and management strategies.
MIS 2 is defined as a postinfectious multisystem inflammatory syndrome occurring after exposure to certain pathogens, distinguished from conditions such as Kawasaki disease, Toxic shock syndrome, Hemophagocytic lymphohistiocytosis, and immune-mediated sequelae described after Influenza pandemic of 1918–1919 and 2009 flu pandemic. Classification schemes developed by groups at American Academy of Pediatrics, European Society for Paediatric Infectious Diseases, and regional public health agencies stratify severity, organ involvement, and laboratory criteria. Subtypes are often categorized by predominant organ system, for example cardiac-predominant, gastrointestinal-predominant, and neurologic-predominant forms, mirroring classifications used by American Heart Association in related pediatric inflammatory conditions.
Patients with MIS 2 typically present with persistent fever, rash, mucocutaneous changes, conjunctivitis, hypotension, and varying degrees of cardiac dysfunction that may resemble presentations seen in Pediatric sepsis cohorts managed at centers like Mayo Clinic and Cleveland Clinic. Laboratory evaluation often shows elevated inflammatory markers including C-reactive protein and ferritin, lymphopenia, and elevated troponin or B-type natriuretic peptide when myocarditis is present; these laboratory patterns echo panels used in workups at Massachusetts General Hospital and Royal Brompton Hospital. Diagnostic algorithms incorporate clinical criteria, exposure history, and exclusion of alternative diagnoses such as Bacterial meningitis, Staphylococcal infections, or autoimmune diseases managed at institutions like John Radcliffe Hospital and Karolinska University Hospital.
Etiologic investigations implicate dysregulated immune responses to antecedent infections, with mechanisms studied in immunology labs at National Institutes of Health, Institut Pasteur, and Scripps Research. Proposed pathophysiologic processes include superantigen-mediated T-cell activation, antibody-dependent enhancement, immune complex deposition, and endothelial injury similar to pathways described in research on Rheumatic fever, Guillain–Barré syndrome, and postinfectious syndromes following Streptococcus pyogenes or Campylobacter jejuni infections. Genetic susceptibility loci identified in genome-wide association studies at Wellcome Trust Sanger Institute and Broad Institute suggest polymorphisms in genes regulating innate immunity and cytokine signaling, paralleling findings in cohorts studied at University of Toronto and Imperial College London.
Management principles include hemodynamic stabilization, immunomodulation, and targeted organ support following protocols developed at Boston Children's Hospital, Seattle Children's Hospital, and The Hospital for Sick Children (Toronto). First-line therapies commonly include intravenous immunoglobulin, corticosteroids, and biologic agents such as anti-IL-1 or anti-IL-6 monoclonal antibodies, drawing on clinical trial designs from National Institute for Health and Care Research and therapeutic experience at UCLA Health. Anticoagulation strategies and cardiac monitoring protocols are often adapted from pediatric cardiology guidelines issued by European Society of Cardiology and American College of Cardiology for myocarditis and coronary involvement. Multidisciplinary teams including specialists from Rashid Hospital style networks coordinate supportive care, rehabilitation, and follow-up.
Short-term prognosis is variable, with many patients responding to timely immunotherapy but a subset developing persistent cardiac dysfunction, coronary artery abnormalities, or neurologic sequelae documented in longitudinal cohorts followed at St George's Hospital and Guy's and St Thomas' NHS Foundation Trust. Complications may mirror those seen in severe inflammatory syndromes such as shock, arrhythmia, and thromboembolic events noted in registries maintained by European Centre for Disease Prevention and Control and Pediatric Health Information System (PHIS). Long-term outcomes remain under investigation in studies at Children's Hospital of Philadelphia and Vanderbilt University Medical Center.
Epidemiologic characterization relies on surveillance by agencies including World Health Organization, Centers for Disease Control and Prevention, and national public health institutes in United Kingdom, France, Germany, Japan, and Australia. Incidence peaks in certain pediatric age ranges and shows temporal association with waves of respiratory or other infectious outbreaks previously tracked during events like the SARS epidemic and H1N1 influenza pandemic. Risk factors under evaluation include prior infection exposure, genetic predisposition, and sociodemographic variables reported in cohort studies from Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine.
Recognition emerged from case series and multicenter collaborations led by teams at Imperial College London, Columbia University Irving Medical Center, and Mount Sinai Health System. Ongoing research includes randomized trials, immunologic profiling, and vaccine safety surveillance coordinated through networks such as Global Research Collaboration for Infectious Disease Preparedness and funding agencies like National Institutes of Health and European Commission. Future priorities mirror agendas from symposia at Royal Society and American Academy of Pediatrics meetings: defining biomarkers, refining treatment algorithms, and establishing long-term registries through consortia including Pediatric Research in Office Settings and international pediatric research collaborations.